Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2004

View Archived Issues

Exelixis makes significant progress in expanding and advancing development pipeline during Q1

Nuvelo expands pipeline to three cardiovascular candidates

Nektar Therapeutics reports positive developments on late-stage programs

Effective wound healing by topical application of novel preclinical therapeutic peptides

Leptin accelerates wound angiogenesis in vivo

Latest phase III data on exenatide in type 2 diabetes presented at ADA

Tripep receives approval to conduct alphaHGA microdosing study

Wyeth reviews R&D pipeline

MDI-based insulin regimen is more cost-effective than CSII

Successful islet cell transplantation using the Edmonton protocol

CV Therapeutics and FDA agree on Ranexa study protocol

Positive phase III results for Aryplase in MPS VI

Solvay reviews bifeprunox development

V.I. Technologies to merge with Panacos

New phase II study of ABT-874 for MS

Iconix to provide advanced chemogenomic profiling services to AstraZeneca

Data on intratumoral injection of INGN-241 in advanced cancer patients

Trillium Therapeutics inlicenses cytokine receptor antagonist program

Enrollment completed in CONFIRM 1 study of PTK/ZK for colorectal cancer

Clofarabine NDA accepted for priority review

Strattera receives U.K. approval

LL-37 demonstrates angiogenic activity in vitro

Cannabinoid receptor partial agonist with antihyperalgesic and antiallodynic effects in vivo

SD-208 shows promise in models of pulmonary fibrosis

Losartan reduces lung injury in preclinical studies

Gilead claims new HIV integrase inhibitors

New bone resorption inhibitors targeting OCIF presented by Sankyo

Novel GAL3 antagonists and their use in depression and anxiety treatment

New hypoglycemic agents developed by Yissum and Hadasit researchers

Sumitomo patent covers novel agents for use in autoimmune diseases

New dopaminergic and serotonergic agents identified at ProteoSys

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...